Invention:
This invention pertains to the use of myelin breakdown products, such as lipids indicative of brain lipid catabolism, as plasma biomarkers for the diagnosis and prognosis of ischemic stroke (IS). Researchers discovered an acute signature of brain lipid catabolism in the plasma 24 hours after a stroke in mouse model research. Notably, a substantial proportion of these elevated lipids and metabolites were essential components of myelin. These experimental results offer insight into the metabolic alterations that occur in the plasma after a stroke and highlight the potential of myelin degradation products as biomarkers of neurodegeneration.
Background:
According to the Stroke Awareness Foundation, ischemic strokes are the most common type of stroke, representing about 87% of all cases. In one second, 32,000 brain cells die, and within 59 seconds, an ischemic stroke will have killed 1.9 million brain cells. Ischemic stroke is a leading cause of mortality and long-term disability worldwide, emphasizing the need for advancements in diagnostic methodologies to improve patient outcomes.
This technology enables early detection of metabolic changes in the plasma following a stroke, which is crucial for timely intervention, potentially reducing the extent of brain damage and improving patient outcomes. Unlike traditional imaging methods, plasma biomarker analysis is non-invasive and can offer real-time insights into the body's metabolic and inflammatory responses. This dynamic analysis is essential for adapting treatment plans to the evolving condition of the patient. By understanding the specific lipidomic signatures associated with stroke, healthcare providers can tailor treatment plans to this disease, enhancing therapeutic effectiveness.
The identification of myelin breakdown products as biomarkers also opens new research avenues, potentially leading to the discovery of novel therapeutic targets and strategies for treating ischemic stroke. With better diagnostic tools and more precise monitoring, long-term outcomes for stroke patients can be significantly improved, reducing the rates of mortality and long-term disability associated with ischemic stroke.
Applications:
- Novel myelin breakdown product biomarker for ischemic stroke diagnosis and prognosis
Advantages:
- Furthered insight into the metabolic operations occurring during IS
- Examines the potential of brain lipid catabolism
- Improves possibility of accuracy in IS diagnosis and prognosis
- Mouse model experimental data available
